Terminated PHASE2 INTERVENTIONAL 2-arm NCT00045591

Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer

Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Breast Cancer

Interventions Celecoxib celecoxib

Updated 7 times since 2017 Last updated: Jan 9, 2017 Started: Feb 28, 2003 Primary completion: Aug 31, 2005 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Alliance for Clinical Trials in Oncology

See all terminations from Alliance for Clinical Trials in Oncology

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

This PHASE2 trial investigates Breast Cancer and is currently terminated or withdrawn. Alliance for Clinical Trials in Oncology leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States , Asheville, United States , Baltimore, United States , Boston, United States , Buffalo, United States , Burlington, United States , Camden, United States , Chapel Hill, United States , Charlottesville, United States , Chicago, United States and 48 more locations